BHVN vs BIIB
BHVN: Biohaven is a biopharmaceutical firm developing a diverse pipeline of innovative therapies for complex diseases in neuroscience, immunology, obesity, and oncology. BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA.
Side-by-side fundamentals
| Metric | BHVN | BIIB | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $11.81 | $243.10 | |
| Market cap | $1.8B | $35.9B | |
| P/E as of 2026-10-20 | n/a | 26.14 | |
| Net margin FY2025, SEC XBRL | n/a | +13.1% | |
| Operating margin FY2021, SEC XBRL | n/a | +25.9% | |
| ROE FY2025, SEC XBRL | -1418.8% | +7.1% | BIIB higher |
| ROA FY2025, SEC XBRL | -163.7% | +4.4% | BIIB higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-03-31 | n/a | 0.34 | |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +2.2% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.53 | 0.50 | |
| 1-year return as of 2026-10-20 close | -32.7% | +65.8% | BIIB higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.